Cardiovascular diagnostics company Lantheus Holdings sets terms for $125 million IPO


Shutterstock photo

Lantheus Holdings, which sells medical imaging agents used in the diagnosis of cardiovascular diseases, announced terms for its IPO on Thursday. The North Billerica, MA-based company plans to raise $125 million by offering 9.3 million shares at a price range of $12 to $15. At the midpoint of the proposed range, Lantheus would command a fully diluted market value of $370 million.

Lantheus Holdings, which traces its roots to 1956 and booked $286 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol LNTH. Citi and Jefferies are the joint bookrunners on the deal. It is expected to price during the week of July 28, 2014.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by